Detection of left ventricular hypertrophy in rats administered a peroxisome proliferator-activated receptor α/γ dual agonist using natriuretic peptides and imaging

Toxicological Sciences

Volumn 114, Issue 2, 2009, Pages 183-192

  Engle, Steven K ^a   Solter, Philip F ^b   Credille, Kelly M ^a   Bull, Christopher M ^a,c   Adams, Stephanie ^a,c   Berna, Michael J ^a   Schultze, Albert E ^a   Rothstein, Emily C ^a   Cockman, Michael D ^a,c   Pritt, Michael L ^a   Liu, Hong ^a   Lu, Yuefeng ^a,c   Chiang, Alan Y ^a   Watson, David E ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c Department of Molecular and Anatomical Imaging   (United States)

Author keywords

Biomarkers; Left ventricular hypertrophy; Natriuretic peptides; PPAR

Indexed keywords

AMINO TERMINAL PRO ATRIAL NATRIURETIC PEPTIDE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC PEPTIDE PRECURSOR; BRAIN NATRIURETIC PEPTIDE PRECURSOR; LY 510929; LY 590929; MYOSIN HEAVY CHAIN BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; TROPONIN I; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEART RATE; HEART WEIGHT; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RAT;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FEMALE; HEART; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; ORGAN SIZE; PEPTIDE FRAGMENTS; PHENYLPROPIONATES; PPAR ALPHA; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; THIOPHENES; TROPONIN T;

RATTUS;

EID: 77951549356     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp311     Document Type: Article

References (42)

1. Arakawa, K., Ishihara, T., Aoto, M., Inamasu, M., Kitamura, K., and Saito, A. (2004). An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. Clin. Exp. Pharmacol. Physiol. 31, 8-13.
2. Artham, S. M., Lavie, C. J., Milani, R. V., Patel, D. A., Verma, A., and Ventura, H. O. (2009). Clinical impact of left ventricular hypertrophy and implication for regression. Prog. Cardiovasc. Dis. 52, 153-167.
3. Asakawa, M., Takano, J., Nagai, T., Uozumi, J., Hasegawa, H., Kubota, N., Saito, T., Masuda, Y., Kadowaki, T., and Komuro, I. (2002). Peroxisome proliferator-activated receptor c plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105, 1240-1246.
4. Berna, M., Ott, L., Engle, S., Watson, D., Solter, P., and Ackermann, B. (2008). Quantification of NTproBNP in rat serum using immunoprecipatiation and LC/MS/MS: a biomarker of drug-induced cardiac hypertrophy. Anal. Chem. 80, 561-566.
5. Berthou, L., Duverger, N., Emmanuel, F., Langouet, S., Auwerx, J., Guillouzo, A., Fruchart, J., Rubin, E., Denefle, P., Staels, B., et al. (1996). Opposite regulation of human versus mouse apolipoprotein A-1 by fibrates in human apolipoprotein A-1 transgenic mice. J. Clin. Invest. 97, 2408-2416.
6. Booz, G. W. (2005). Putting the brakes on cardiac hypertrophy exploiting the NO-cGMP counter-regulatory system. Hypertension 45, 341-346.
7. Davis, M. E., Richards, A. M., Nicholls, M. G., Yandle, T. G., Frampton, C. M., and Troughton, R. W. (2006). Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113, 977-985.
8. Dietz, J. R. (2005). Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc. Res. 68, 8-17.
9. Doust, J. A., Glasziou, P. P., Pietrzak, E., and Dobson, A. J. (2004). A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch. Intern. Med. 164, 1978-1984.
10. Duan, S. Z., Ivashchenko, C. Y., Russel, M. W., Milstone, D. S., and Mortensen, R. M. (2007). Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-γ both induce cardiac hypertrophy in mice. Circ. Res. 97, 372-379.
11. Dunnett, C. W. (1964). New tables for multiple comparisons with a control. Biometrics 20, 482-491.
12. Edgley, A. J., Thalén, P. G., Dahllöf, B., Lanne, B., Ljung, B., and Oakes, N. D. (2006). PPARc agonist induced cardiac enlargement is associated with reduced fatty acid and increased glucose utilization in myocardium of Wistar rats. Eur. J. Pharmacol. 538, 195-206.
13. Etgen, G., Broderick, C., Oldham, B., Bean, J., Bensch, W., Montrose, C., Barr, R., Zink, R., Jett, D., Liu, S., et al. (2003). LY510929: a highly potent, Non-TZD PPAR[alpha], [gamma] dual agonist for the treatment of type 2 diabetes and associated dyslipidemia. Diabetes 52, A141 (Abstract).
14. Finck, B. N., Han, X., Courtois, M., Aimond, F., Nerbonne, J. M., Kovacs, A., Gross, R. W., and Kelly, D. P. (2003). A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl. Acad. Sci. U.S.A. 100, 1226-1231.
15. Galasko, G., Collinson, P. O., Barnes, S. C., Gaze, D., Lahiri, A., and Senior, R. (2007). Comparison of the clinical utility of atrial and B type natriuretic peptide measurement for the diagnosis of systolic dysfunction in a low-risk population. J. Clin. Pathol. 60, 570-572.
16. Greene, A. N., Clapp, S. L., and Alper, R. H. (2007). Timecourse of recovery after surgical intraperitoneal implantation of radiotelemetry transmitters in rats. J. Pharmacol. Toxicol. 56, 218-222.
17. Grossman, W., Jones, D., and McLaurin, L. P. (1975). Wall stress and patterns of hypertrophy in the human left ventricle. J. Clin. Invest. 56, 56-64.
18. Hanton, G., Eder, V., Rochefort, G., Bonnet, P., and Hyvelin, J. (2008). Echocardiography, a non-invasive method for the assessment of cardiac function and morphology in preclinical drug toxicology and safety pharmacology. Expert Opin. Drug Metab. Toxicol. 4, 681-696.
19. Hunter, J. J., and Chien, K. R. (1999). Signaling pathways for cardiac hypertrophy and failure. N. Engl. J. Med. 341, 1276-1283.
20. Kimura, K., Yamaguchi, Y., Horii, M., Kawata, H., Yamamoto, H., Uemura, S., and Saito, Y. (2007). ANP is cleared much faster than BNP in patients with congestive heart failure. Eur. J. Clin. Pharmacol. 63, 699-702.
21. Krauser, D. G., and Devereaux, R. B. (2006). Ventricular hypertrophy and hypertension: prognostic elements and implications for management. Herz 31, 305-316.
22. Langenickel, T., Pagel, I., Höhnel, K., Dietz, R., and Willenbrock, R. (2000). Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Am. J. Physiol. Heart Circ. Physiol. 278, H1500-H1506.
23. Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., and Castelli, W. P. (1990). Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322, 1561-1566.
24. Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408.
25. Makino, N., Sugano, M., Satoh, S., Oyama, J., and Maeda, T. (2006). Peroxisome proliferator-activated receptor-γ ligands attenuate brain natriuretic peptide production and affect remodeling in cardiac fibroblasts in reoxygenation after hypoxia. Cell Biochem. Biophys. 44, 65-71.
26. Miller, A. R., and Etgen, G. J. (2003). Novel Peroxisome proliferator-activated receptor ligands for type 2 diabetes and the metabolic syndrome. Expert Opin. Investig. Drugs 12, 1489-1500.
27. Miller, R. G., Jr. (1981) Simultaneous Statistical Inference, 2nd ed., pp. 67-69. Springer-Verlag, New York.
28. Pfützner, A., Marx, N., Lübben, G., Langenfeld, M., Walcher, D., Konrad, T., and Forst, T. (2005). Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control. J. Am. Coll. Cardiol. 45, 1925-1931.
29. Sabrane, K., Kruse, M. N., Fabritz, L., Zetsche, B., Mitko, D., Skryabin, B. V., Zwiener, M., Baba, H. A., Yanagisawa, M., and Kuhn, M. (2005). Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J. Clin. Invest. 115, 1666-1674.
30. Sagnella, G. A. (1998). Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin. Sci. 95, 519-529.
31. Schirmer, H., and Omland, T. (1999). Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. Eur. Heart J. 20, 755-763.
32. 2-terminal fragment of rat pro-atrial natriuretic factor in the circulation: identification, radioimmuno-assay and half-life. Peptides 9, 47-53.
33. Toischer, K., Kögler, H., Tenderich, G., Grebe, C., Seidler, T., Van, P. N., Jung, K., Knöll, R., Körfer, R., and Hasenfuss, G. (2008). Elevated afterload, neuroendocrine stimulation, and human heart failure increase BNP levels and inhibit preload-dependent SERCA upregulation. Circ. Heart Fail. 1, 265-271.
34. Tsuruda, T., Boerrigter, G., Huntley, B. K., Noser, J. A., Cataliotti, A., Costello-Boerrigter, L. C., Chen, H. H., and Burnett, J. C. (2002). Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ. Res. 91, 1127-1134.
35. Tukey, J. W., Ciminera, J. L., and Heyse, J. F. (1985). Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 41, 295-301.
36. Van Vleet, J. F., and Ferrans, V. J. (1995). Pathology of the cardiovascular system. In Thomson's Special Veterinary Pathology (W. W. Carlton and M. D. McGavin, Eds.), pp. 189. Mosby, St Louis, MO.
37. Verreth, W., Ganame, J., Mertens, A., Bernar, H., Herregods, M., and Holvoet, P. (2006). Peroxisome proliferator-activated receptor-α,γ-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice. Arterioscler. Thromb. Vasc. Biol. 26, 922-928.
38. Weaver, D. J., Kimball, T. R., Koury, P. R., and Mitsnefes, M. M. (2009). Cardiac output and associated left ventricular hypertrophy in pediatric chronic kidney disease. Pediatr. Nephrol. 24, 565-570.
39. Winer, B. J. (1971). Design and analysis of single-factor experiments. In Statistical Principles in Experimental Design, 2nd ed., pp. 149-260. McGraw-Hill, New York.
40. Xu, Y., Rito, C. J., Etgen, G. J., Ardecky, R. J., Bean, J. S., Bensch, W. R., Bosley, J. R., Broderick, C. L., Brooks, D. A., Dominianni, S. J., et al. (2004). Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/ gamma agonists. J. Med. Chem. 47, 2422-2425.
41. Yokota, N., Bruneau, B. G., de Bold, M. L. K., and de Bold, A. J. (1994). Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon. J. Clin. Invest. 94, 1938-1946.
42. Young, M. E., Laws, F. A., Goodwin, G. W., and Taegtmeyer, H. (2001). Reactivation of peroxisome proliferator-activated receptor a is associated with contractile dysfunction in hypertrophied rat heart. J. Biol. Chem. 276, 44390-44395.